Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.

•Survival of organ transplant recipients with lung cancer is reduced compared to historical norms in non-transplant patients.•Those treated with definitive therapy instage III and chemotherapy in stage IV NSCLC had survivals matching historic norms.•Adverse events from chemotherapy appear higher in transplant recipients and appear lessened with dose reductions.•Treated SCLC patients had survivals slightly lower than historic norms.